References
- Bugelski, P. J., Volk, A., Walker, M. R., et al. 2010. Critical review of pre-clinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Intl. J. Toxicol. 29:435–466
- Dooley, M. A., and Ginzler, E. M. 2006. Newer therapeutic approaches for systemic lupus erythematosus: Immunosuppressive agents. Rheum. Dis. Clin. North. Am. 32:91–102
- Egenolf, D. D., Rafferty, P., Brosnan, K., et al. 2011. Development of a murine model of lymph node metastases suitable for immunotoxicity studies. J. Pharmacol. Toxicol. Meth. 63:236–249
- Hernandez, L. G., van Steeg, H., Luijten, M., and van Benthem, J. 2009. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat. Res. 682:94–109
- Hume, D. M., Merrill, J. P., Miller, B. F., and Thorn, G. W. 1955. Experiences with renal homo-transplantation in the human: Report of nine cases. J. Clin. Invest. 34:327–382
- Khariwala, S. S., Kjaergaard, J., Lorenz, R., et al. 2006. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116:814–820
- Khurana, D., Martin, E. A., Kasperbauer, J. L., et al. 2001. Characterization of a spontaneously-arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 23:899–906
- Kurki, P. T. 1992. Safety aspects of the long term cyclosporin A therapy. Scand. J. Rheumatol. Suppl. 95:35–38
- O’Malley B.W. Jr, Cope, K. A., Johnson, C. S., and Schwartz, M. R. 1997. A new immuno-competent murine model for oral cancer. Arch. Otolaryngol. Head Neck Surg. 123:20–24
- Rafferty, P., Egenolf, D., Brosnan, K., et al. 2012. Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice. J. Immunotoxicol. 9:43–55
- Schreiber, R. D., Old, L. J., and Smyth, M. J. 2011. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570
- Schulz, T. F. 2009. Cancer and viral infections in immunocompromised individuals. Intl. J. Cancer 125:1755–1763
- Ulrich, C., Kanitakis, J., Stockfleth, E., and Euvrard, S. 2008. Skin cancer in organ transplant recipients - where do we stand today? Am. J. Transplant. 8:2192–2198
- Vahle, J. L., Finch, G. L., Heidel, S. M., et al. 2010. Carcinogenicity assessments of biotechnology–derived pharmaceuticals: A review of approved molecules and best practice recommendations. Toxicol. Pathol. 38:522–553
- Vial, T., and Descotes, J. 2003. Immunosuppressive drugs and cancer. Toxicology 185:229–240
- Weischer, M., Rocken, M., and Berneburg, M. 2007. Calcineurin inhibitors and rapamycin: Cancer protection or promotion? Exp. Dermatol. 16:385–393
- Wong, R. J., Chan, M. K., Yu, Z., et al. 2004. Angiogenesis inhibition by an oncolytic herpes virus expressing IL-12. Clin. Cancer Res. 10:4509–4516
- Wong, R. J., Patel, S. G., Kim, S., et al. 2001. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Human Gene Ther. 12:253–265